ChromaDex Announces the Launch of BluScience™, a Breakthrough Supplement Line, Nationwide At GNC Stores and On GNC.com

IRVINE, Calif., June 13, 2011 /PRNewswire/ -- The company today announced the launch of BluScience, its new line of dietary supplements which feature pTeroPure® and will be available in July at GNC (NYSE: GNC) stores nationally and online at GNC.com.

(Logo:  http://photos.prnewswire.com/prnh/20110613/LA18353LOGO)

"We are extremely excited about the BluScience launch with GNC, given the innovative and novel ingredient pTeroPure, which is the foundation for the BluScience line," said Ted Deitrick, Vice President, Merchandising for GNC. "The BluScience products will be rolled out to all corporate stores nationwide beginning in July as an addition to the GNC commitment to health."

"The launch of BluScience represents a major milestone in our company's growth and in the accelerating commercialization of pTeroPure," said William Spengler, President of ChromaDex. "We are very proud to partner with GNC in our first national consumer launch. BluScience is a natural product offering designed to serve over half of the US population that considers supplement and vitamin use to be an integral part of a healthy and balanced lifestyle."

Blueberries are well-regarded for their powerful health benefits. A major component lending those health benefits is pterostilbene, a unique nutrient that functions as part of the plant's defense system. ChromaDex (OTCBB: CDXC) has perfected a proprietary method to make pTeroPure, an ultra-pure pterostilbene.

New products available through the BluScience line include HeartBlu for healthy heart support, which contains pTeroPure, blueberry extract and phytosterols. EternalBlu contains pTeroPure and other anti-oxidants that support cellular health and minimize the effects of oxidative stress. TrimBlu contains pTeroPure, jojoba and other vitamins and minerals to support metabolism. Blu2Go, a melt, contains pTeroPure and caffeine for energy support.

About ChromaDex

ChromaDex is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries.  The company has an impressive pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights.  

About GNC Holdings, Inc.

GNC Holdings, Inc., headquartered in Pittsburgh, Pa., is a leading global specialty retailer of health and wellness products, including vitamins, minerals, and herbal supplement products, sports nutrition products and diet products, and trades on the New York Stock Exchange under the symbol "GNC".

As of March 31, 2011, GNC has more than 7,300 locations, of which more than 5,600 retail locations are in the United States (including 895 franchise and 2,029 Rite Aid franchise store-within-a-store locations) and franchise operations in 48 countries (including distribution centers where retail sales are made). The Company - which is dedicated to helping consumers Live Well - is a diversified, multi-channel business model that derives revenue from product sales through company-owned retail stores, domestic and international franchise activities, third party contract manufacturing, e-commerce, and corporate partnerships. Our broad and deep product mix, which is focused on high-margin, premium, value-added nutritional products, is sold under GNC proprietary brands, including Mega Men, Ultra Mega, GNC Wellbeing, Pro Performance, and Longevity Factors, and under nationally recognized third party brands.

ChromaDex Forward Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

ChromaDex Investor Inquiries:
Liviakis Financial Communications, Inc.
John M. Liviakis, President
415-389-4670
[email protected]

Media Inquiries:
Carolyn Hawley
Canale Communications
619-849-5375
[email protected]

SOURCE ChromaDex Corporation